Table 1.
Patient characteristics
| Total (n = 232, %) | |
|---|---|
| Gender | |
| Male | 185 (79.7) |
| Female | 47 (20.3) |
| Age | |
| ≤ 62 years | 127 (54.7) |
| > 62 years | 105 (45.3) |
| ECOG-PS | |
| 0 | 162 (69.8) |
| 1–2 | 70 (30.2) |
| Tumor stage* | |
| II | 58 (25.0) |
| III + IV | 174 (75.0) |
| Tumor location | |
| Cervical + upper | 137 (59.1) |
| Middle + lower + multiple | 95 (40.9) |
| Length | |
| ≤ 5.0 cm | 118 (50.9) |
| > 5.0 cm | 114 (49.1) |
| Radiotherapy dose | |
| 61.2 Gy | 220 (94.8) |
| 50.4 ~ < 61.2 Gy | 12 (5.2) |
| Chemo regimen | |
| PF | 64 (27.6) |
| TF | 102 (44.0) |
| TP | 30 (12.9) |
| TC | 36 (15.5) |
| Concurrent chemo completion | |
| Yes | 197 (84.9) |
| No | 35 (15.1) |
| Consolidation chemo cycles | |
| 2 cycles | 178 (76.7) |
| 0–1 cycle | 54 (23.2) |
ECOG-PS: Eastern Cooperative Oncology Group performance status; PF: fluorouracil (5-FU) with cisplatin (DDP); TC: PTX with carboplatin (CBP); TF: 5-FU with paclitaxel (PTX); TP: PTX with DDP
*According to AJCC 6th